Last update 31 Mar 2025

ZL-1310

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
YL 212, YL-212, ZL 1310
Action
inhibitors
Mechanism
DLL3 inhibitors(Delta-like protein 3 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastro-Enteropancreatic Neuroendocrine TumorPhase 2-01 Apr 2025
Large cell neuroendocrine carcinoma of lungPhase 2-01 Apr 2025
Locally Advanced Malignant Solid NeoplasmPhase 2-01 Apr 2025
MelanomaPhase 2-01 Apr 2025
Metastatic castration-resistant prostate cancerPhase 2-01 Apr 2025
Non-Small Cell Lung CancerPhase 2-01 Apr 2025
Prostate Neuroendocrine CarcinomaPhase 2-01 Apr 2025
Small Cell Lung CancerPhase 2-01 Apr 2025
Extensive stage Small Cell Lung CancerPhase 1
United States
23 Jan 2024
Extensive stage Small Cell Lung CancerPhase 1
United States
23 Jan 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
25
ajoskbjezj(sljvveyhpi) = ahwrwmhkso zzwpcfqyvp (spqtsxszbk, 48.8 - 90.9)
Positive
24 Oct 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free